This price target is based on 0 analysts offering 12 month price targets for Tyme Technologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.07 Tyme Technologies' current and average target prices are 1.78 and 8.83, respectively. The current price of Tyme Technologies is the price at which Tyme Technologies is currently trading. On the other hand, Tyme Technologies' target price is what analysts think the stock is worth or could sell for in the future Tyme Technologies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. TYME updated stock price target summary Find the latest Tyme Technologies, Inc. TYME analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. TYME Tyme Technologies, Inc. Tyme Technologies Inc's average analyst price target is higher than 18.47% of all US stocks. Stocks similar to Tyme Technologies Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are EVFM, HOTH and BBI. What is the outlook for TYME? Use POWR Ratings for clearer insight into price direction
Find real-time TYME - Tyme Technologies Inc stock quotes, company profile, news and forecasts from CNN Business. Price/Sales--Price/Book: 1.78: Competitors Today's change Today' The Tyme Technologies Inc stock price fell by -3.45% on the last day (Tuesday, 13th Jul 2021) from $1.16 to $1.12. and has now fallen 3 days in a row. During the day the stock fluctuated 4.50% from a day low at $1.11 to a day high of $1.16. The price has fallen in 8 of the last 10 days and is down by -15.15% for this period
Tyme Technologies Inc () Stock Market info Recommendations: Buy or sell Tyme Technologies stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Tyme Technologies share forecasts, stock quote and buy / sell signals below.According to present data Tyme Technologies's TYME shares and potentially its market environment have been in bearish cycle last 12. Tyme Technologies, Inc. Common Stock (TYME) Nasdaq Listed. Nasdaq 100. $1.20. Unchanged. CLOSED AT 4:00 PM ET ON Jul 06, 2021. Data is currently not available. $1.19 Over the past 30 days, the shares of Tyme Technologies Inc. (NASDAQ:TYME) have changed -20.53%. Wall Street analysts have a consensus price target for the stock at $8.00, which means that the shares' value could jump 85.5% from the levels at last check today. The projected low price target is $8.00 while the price target rests at a high of $8.00
Tyme Technologies, Inc. Common Stock (TYME) Nasdaq 2 days ago TYME TECHNOLOGIES DL-0001 (RFL.F) stock forecast and price target TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock. Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based. The latest price target for Tyme Technologies (NASDAQ: TYME) was reported by Canaccord Genuity on January 4, 2018. The analyst firm set a price target for 10.00 expecting TYME to rise to within 12.. Further, Tyme Technologies, Inc. (TYME) has a beta value of 1.05, and an average true range (ATR) of 0.13. Analysts have given the company's stock an average 52-week price target of $8, forecast between a low of $8 and high of $8 Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an.
The projected low price target is $8.00 while the price target rests at a high of $8.00. In that case, then, we find that the latest price level in today's session is -344.44% off the targeted high while a plunge would see the stock gain -344.44% from the levels at last check today. Tyme Technologies Inc. (TYME) estimates and forecast The average price target is $9.5, which means analysts expect the stock to rise by 603.70% over the next twelve months. That average ranking earns Tyme Technologies Inc an Analyst Rating of 79, which is better than 79% of stocks based on data compiled by InvestorsObserver. Wall Street analysts are rating TYME a Strong Buy today Why Tyme Stock Got Demolished Today Friday, 8 January 2021 Price target. Current $1.50. Average $8.17. Low $7 High $10. Tyme Technologies Inc executives Insider Age Since Compensation; James Biehl (56) Chief Legal Officer and Corporate Secretary since 2018 56: Tyme Technologies, Inc., is an emerging biotechnology company developing. Further, Tyme Technologies, Inc. (TYME) has a beta value of 0.99, and an average true range (ATR) of 0.08. Analysts have given the company's stock an average 52-week price target of $8, forecast between a low of $8 and high of $8
Wall Street is positive on Tyme Technologies Inc (TYME). On average, analysts give TYME a Strong Buy rating. The average price target is $9.5, which means analysts expect the stock to add by 508.97% over the next twelve months Tyme Technologies Inc • Biotechnology Fri 9 Jul, close Current 1 day ago 2 days ago 3 days ago 4 days ago 5 days ago 6 days ago 7 days ago 8 days ago 9 days ago 10 days ago 11 days ago 12 days ago 13 days ago 14 days ago 15 days ago 16 days ago 17 days ago 18 days ago 19 days ago 20 days ago 21 days ago 22 days ago 23 days ago 24 days ago 25.
On May 10, 2021, TYME Technologies, Inc. (Nasdaq: Analysts have a BUY recommendation on the stock with a $9.5/share price target for a 480% gain with respect to the current $1.36/share Now has 2 analysts covering the stock with a consensus rating of STRONG BUY.... target price ranges between 9.5 and 8 with a mean target price of 8.75 — at the current price, this indicates a potential UPSIDE of over 380%. TYME technologies is 1.22 and has a buy rating of 4 and hold of 1 sell 0, with an average price of 8.23$ a share, its.
Tyme Technologies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RFL.DE updated stock price target summary TYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Feb 4, 2021 TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19. TYME TECHNOLOGIES INC stock price forecast for further price development up to 10.14% (time horizon: 1 day) and price target of 1.28 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) TYME TECHNOLOGIES INC share price prediction for 2021-09-03 with daily closed price projection TYME TECHNOLOGIES, INC. (NASDAQCM : TYME) dropped from Russell 3000E Index. TYME Technologies, Inc. is a biotechnology company. The Company is focused on developing cancer metabolism-based therapies (CMBTsTM) for solid tumors and hematologic cancers. The Companyâ€™s lead clinical CMBT compound, SM-88, is an oral investigational modified. Tyme Technologies, TYME: Overview with real-time Short Interest, Analysts Estimates, Insiders, Director Dealings, Valuation, EPS, DPS, News, Peers, Events, Short Interests and more. Target Price N/A Return Potential 0.00 % Stock Last Trading Day 1 Week Sensitivity Effect Score (1W) Show on char
However, the potential for rewards is obvious. So, if you think Tyme Tech is a company that can deliver cancer-combating products to the market, now may be the right time to pull the trigger. Tyme Technologies price forecast 2021. Our 12-month TYME price target is as follows: $8 Tyme Technologies Inc (NASDAQ: TYME) shares are nearly doubling on above-average volume Wednesday. Tyme, which focuses on developing cancer metabolism-based therapies, said the U.S. Patent and. .m. EST today, after the company reported fiscal third-quarter results. Tyme also launched an at-the-market (ATM) stock offering This price target is based on 1 analysts offering 12 month price targets for IntelGenx Technologies in the last 3 months. The average price target is $1.20, with a high forecast of $1.20 and a low forecast of $1.20. The average price target represents a 166.67% upside from the last price of $0.45 Based on TYME analyst price targets, TYME stock forecast is $8.00 (for a year from now). That means the average analyst price target for TYME stock is $8.00. The prediction is based on 1 analyst estimates. The low price target for TYME is $8.00, while the high price target is $8.00. TYME analyst rating is Strong Buy
The last trading period has seen Tyme Technologies Inc. (TYME) move -78.56% and 25.88% from the stock's 52-week high and 52-week low prices respectively. The daily trading volume for Tyme Technologies Inc. (NASDAQ:TYME) over the last session is 1.96 million shares Tyme Technologies Inc. (NASDAQ: TYME) stock closed at 1.08 per share at the end of the most recent trading day (a -2.7 % change compared to the prior day closing price) with a volume of 345.17K shares and market capitalization of 185.98M.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people Selected key stats of Tyme Technologies, Inc. (TYME) including 10 year stock price and latest news. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tyme Technologies with a $9.50 average price target, representing a 588.4% upside. In a report issued on June 24, H.C. Wainwright also maintained a Buy rating on the stock with a $9.50 price target
Today, we revisit Tyme Technologies, for the first time in nearly a year. This intriguing oncology play is way under analysts' price targets but the shares have done little in 2020 Company Name: Tyme Technologies Inc., Stock Symbol: TYME, Industry: Medical - Drugs, Total Posts: 786, Last Post: 7/20/2021 1:59:35 P Description: Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter.
Tyme Technologies Inc (NASDAQ: TYME stock makes the perfect target. That analyst has TYME with a rating of Buy and a price target of $9.50 per share, representing the potential for gains. Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it closed its previously announced registered direct offering of 40,000,000 shares of its common stock, par value $0.0001 per share, at a purchase price of $2.50 per share, priced at-the-market.
That analyst has TYME with a rating of Buy and a price target of $9.50 per share, representing the potential for gains in multiples, even after the dramatic premarket run we're seeing this morning. Risks to Consider Before Buying TYME Stock. If you plan on buying TYME stock, or any other stock for that matter, you're going to have to be. Tyme Technologies says it received additional patent claims related to its metabolomic technology platform. The stock recently traded at %1.6450, up 52%. Duolingo Raises the Price Target.
The stock is trading at a volume of 1.4m whereas it usually trades at a volume closer to 550k, probably because of this catalyst coming up. TYME has three FDA catalysts on the line. The first is their SM-88 (Tyme-88-Panc) Phase 2/3 data which is expected on 1/17/2021 at the conference Buy Tyme Technologies (TYME) Jing Jun Ma. Posted Nov 23, 2020. Fact checked. Tyme Technologies, Inc is a biotechnology business based in the US. Tyme Technologies shares (TYME) are listed on the NASDAQ and all prices are listed in US Dollars. Tyme Technologies employs 18 staff and has a market cap (total outstanding shares value) of 0.00 View live Tyme Technologies, Inc chart to track its stock's price action. Find market predictions, TYME financials and market news. SMA50/200 as support Entry 1.5 Stop 1 Target 3.5 Risk management is much more important than a good entry point
Tyme Technologies Inc (TYME) In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Tyme Technologies Inc, with a price target of $9.50. The company's shares closed yesterday at $1.18, close to its 52-week low of $1.12 Finally, boosted their target price on Trinseo from $66.00 to $70.00 in a research report on Tuesday, May 11th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $61.78 Palantir Technologies Inc. (NYSE:PLTR) with the stream of -0.30% also noticed, India Tyme Technologies, Inc. (NASDAQ:TYME) encountered a rapid change of -1.90% in the last hour of Monday's trading session. Palantir Technologies Inc. (NYSE:PLTR) closed at $21.31 and the price was -9.26% so far this year. The price/earnings to growth ratio (PEG ratio) is a stock's price-to-earnings (P/E. The firm noted that, We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030 assuming a 12% discount rate and 2% terminal growth rate Tyme Technologies Inc. (TYME) is priced at $1.55 after the most recent trading session. At the very opening of the session, the stock price was $1.56 and reached a high price of $1.63, prior to closing the session it reached the value of $1.57. The stock touched a low price of $1.54
TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET. TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTstm), today announced that it will host a conference call and live video webcast on Thursday, June 10, 2021 at 5:00 PM ET >> 7 Top Picks for the Post-Pandemic Economy 7 Top Picks for the Post-Pandemic Econom Get (NASDAQ | TYME Tyme Technologies, Inc) latest stock price, analyst ratings, fundamental analysis, ratios, market performance, news, target price and financial repor Tyme Technologies, Inc. (TYME) Quote Average Target Price: stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices.
The Last Price shown is the last trade price at the time the quote page was displayed, and will not update every 10 seconds (as the Last Price at the top of the Quote page does). The Last Price will update only when the page is refreshed. Pivot points are used to identify intraday support, resistance and target levels About Tyme Technologies, Inc. 17 STATE STREET 7TH FLOOR, NEW YORK, New York, 10004, United States +1 212 461-2315. Tyme Technologies Inc is the U.S based clinical-stage biotechnology company The TYME stock was last observed hovering at around $1.65 in the last trading session, with the day's gains setting it 0.05% off its average median price target of $8.00 for the next 12 months. It is also 78.75% off the consensus price target high of $8.00 offered by 1 analysts, but current levels are 78.75% higher than the price target low. Tyme Technologies found using ticker (TYME) have now 2 analysts in total covering the stock. The consensus rating is 'Strong_Buy'. The target price ranges between 9.5 and 8 with the average target price sitting at 8.75. Now with the previous closing price of 2 this now indicates there is a potential upside of 337.5% Therefore, Sesen has a Strong Buy consensus rating. The average price target is $3.42 and indicates possible huge gains of 227% in the coming year. Tyme Technologies (TYME) Time hasn't been kind to biotech Tyme Technologies; 2019 has continued a multi-year trend and has been a bit of a letdown, to say the least
Tyme Technologies Inc has an analyst consensus of Moderate Buy, with a price target consensus of $9.50. See today's analyst top recommended stocks >> The company has a one-year high of $4.64 and a one-year low of $0.92. Currently, Tyme Technologies Inc has an average volume of 822.7K . 4. Sesen Bio Inc. (NASDAQ: SESN) The last biotech penny stock on this list is Sesen Bio. As a late-stage clinical company, its focus is on targeting fusion protein therapeutics
Exela Technologies Stock Forecast, XELA stock price prediction. Price target in 14 days: 4.785 USD. The best long-term & short-term Exela Technologies share price. Tyme Technologies found using ticker (TYME) have now 2 analysts covering the stock. The analyst consensus points to a rating of 'Strong_Buy'. The range between the high target price and low target price is between 9.5 and 8 calculating the mean target price we have 8.75 Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma PennyStock101 Jan 17, 2020. Tyme Technologies, Inc. is a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis Tyme Technologies Inc (NASDAQ:TYME) Expected to Announce Earnings of -$0.07 Per Share Kimberly Clark Corp (NYSE:KMB) Receives $150.10 Average Target Price from Brokerage
This company gets very sparse attention from the analyst community. Only two analysts have chimed in on this stock since our last article in January. On August 27 th, Canaccord Genuity reissued its Buy rating and $8.00 price target on TYME. On November 13 th, H.C. Wainwright reiterated its own Buy rating and $9.50 price target on the shares of. TYME Tyme Technologies In...-0.04-3.15%: MRKR Marker Therapeutics-0.05-2.20%: Data as of 3:59pm ET, 07/23/2021. Financials. Next reporting date: Most stock quote data provided by BATS. Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Tyme Technologies (TYME - Research Report) yesterday and set a price target of $8.00.The company's shares closed last Wednesday at $1.20. According to TipRanks.com, Lee is a 3-star analyst with an average return of 2.7% and a 45.2% success rate. Lee covers the Healthcare sector, focusing on stocks such as Turning Point. Moreover, price targets range from $8 to $12 per share, with a median price target of $10, representing the potential for tremendous gains. TYME Stock: TYME Technologies Heads up on COVID-19. On Thursday, July 16th, Steve Hoffman sold 51,299 shares of Tyme Technologies stock. The stock was sold at an average price of $1.26, for a total value of $64,636.74. Shares of TYME stock opened at $0.98 on Friday. Tyme Technologies Inc has a 12-month low of $0.86 and a 12-month high of $2.04. The business has a 50-day moving average price of.
This target system comes with 147 LEDs, scoring capabilities, timer speeds and double the target size area of LaserLyte's popular and original Laser Training Target. Three timer speeds allow for up to 3 players to challenge each other using the integrated lasers on the Trainer Trigger Tyme Pistols On August 27 th, Canaccord Genuity reissued its Buy rating and $8.00 price target on TYME. On November 13 th, H.C. Wainwright reiterated its own Buy rating and $9.50 price target on the shares of Tyme. The company ended the first half of 2020 with just over $21 million of cash on the balance sheet Quick Tyme joins LaserLyte's growing lineup of fun and safe laser training products. Ideal for concealed carry practice and competitive shooters, the Quick Tyme Target features an integrated stopwatch that counts up from zero seconds until the target is shot with any LaserLyte Laser Trainer. When a laser shot hits the target, the stopwatch. Vir Biotechnology, Inc. (NASDAQ:VIR) insider Phillip Pang sold 4,630 shares of the stock in a transaction that occurred on Wednesday, July 21st. The shares were sold at an average price of $37.44, for a total transaction of $173,347.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through [
The price target of the Visa stock has been increased from a sum of $233 to a sum of $253 in a Monday research report. According to the same report, the brokerage has put up a rating of overweight on the Visa stock. The price target set by Morgan Stanley implies an annual growth rate of about 22.8% on the previous close of the company BEDMINSTER, N.J.--(BUSINESS WIRE)-- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced that it has received.